References
- C. Lin, R. Clark, P. Tu, H. B. Bosworth and L. L. Zullig, Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers, Breast Cancer Res. Treat. 165(2) (2017) 247–260; https://doi.org/10.1007/s10549-017-4317-2
- V. J. O’neill and C. J. Twelves, Oral cancer treatment: developments in chemotherapy and beyond, Br. J. Cancer 87(9) (2002) 933–937; https://doi.org/10.1038/sj.bjc.6600591
- V. Gebbia, G. Bellavia, F. Ferra and M. R. Valerio, Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents, Expert Opin. Drug Saf. 11(1) (2012) 49–59; https://doi.org/10.1517/14740338.2011.645803
- B. A. Given, S. L. Spoelstra and M. Grant, The challenges of oral agents as antineoplastic treatments, Semin. Oncol. Nurs. 27(2) (2011) 93–103; https://doi.org/10.1016/j.soncn.2011.02.003
- R. Lasala and F. Santoleri, Association between adherence to oral therapies in cancer patients and clinical outcome: a systematic review of the literature, Br. J. Clin. Pharmacol. 88(5) (2022) 1999–2018; https://doi.org/10.1111/bcp.15147
- L. A. Decosterd, N. Widmer, K. Zaman, E. Cardoso, T. Buclin and C. Csajka, Therapeutic drug monitoring of targeted anticancer therapy, Biomark Med. 9(9) (2015) 887–893; https://doi.org/10.2217/bmm.15.78
- T. M. Atkinson, V. M. Rodríguez, M. Gordon, I. K. Avildsen, J. C. Emanu, S. T. Jewell, K. A. Anselmi and P. K. Ginex, The association between patient-reported and objective oral anticancer medication adherence measures: a systematic review, Oncol. Nurs. Forum. 43(5) (2016) 576–582; https://doi.org/10.1188/16.ONF.576-582
- K. Ruddy, E. Mayer and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA Cancer J. Clin. 59(1) (2009) 56–66; https://doi.org/10.3322/caac.20004
- A. Vyas, A. Descoteaux, S. Kogut, M. A. Parikh, P. J. Campbell, A. Green and K. Westrich, Predictors of adherence to oral anticancer medications: an analysis of 2010-2018 US nationwide claims, J. Manag. Care Spec. Pharm. 28(8) (2022) 831–844; https://doi.org/10.18553/jmcp.2022.28.8.831
- A. M. Levine, J. L. Richardson, G. Marks, K. Chan, J. Graham, J. N. Selser, C. Kishbaugh, D. R. Shelton and C. A. Johnson, Compliance with oral drug therapy in patients with hematologic malignancy, J. Clin. Oncol. 5(9) (1987) 1469–1476; https://doi.org/10.1200/JCO.1987.5.9.1469
- C. R. Lee, P. W. Nicholson, R. L. Souhami and A. A. Deshmukh, Patient compliance with oral chemo-therapy as assessed by a novel electronic technique, J. Clin. Oncol. 10(6) (1992) 1007–1013; https://doi.org/10.1200/JCO.1992.10.6.1007
- L. Atkins and L. Fallowfield, Intentional and non-intentional non-adherence to medication amongst breast cancer patients, Eur. J. Cancer 42(14) (2006) 2271–2276; https://doi.org/10.1016/j.ejca.2006.03.004
- J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. M. Parkin, M. Piñeros, A. Znaor and F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int. J. Cancer. 144(8) (2019) 1941–1953; https://doi.org/10.1002/ijc.31937
- M. C. Kirk and C. A. Hudis, Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer, Clin. Breast Cancer 8(2) (2008) 155–161; https://doi.org/10.3816/CBC.2008.n.016
- A. H. Partridge, P. S. Wang, E. P. Winer and J. Avorn, Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer, J. Clin. Oncol. 21(4) (2003) 602–606; https://doi.org/10.1200/JCO.2003.07.071
- T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman, Adherence to tamoxifen over the five-year course, Breast Cancer Res. Treat. 99(2) (2006) 215–220; https://doi.org/10.1007/s10549-006-9193-0
- A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli and R. A. Silliman, Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer, J. Clin. Oncol. 22(16) (2004) 3309–3315; https://doi.org/10.1200/JCO.2004.11.064
- T. I. Barron, R. M. Connolly, K. Bennett, J. Feely and M. J. Kennedy, Early discontinuation of tamoxifen: a lesson for oncologists, Cancer 109(5) (2007) 832–839; https://doi.org/10.1002/cncr.22485
- M. Giuliano, F. Schettini, C. Rognoni, M. Milani, G. Jerusalem, T. Bachelot, M. De Laurentiis, G. Thomas, P. De Placido, G. Arpino, S. De Placido, M. Cristofanilli, A. Giordano, F. Puglisi, B. Pistilli, A. Prat, L. Del Mastro, S. Venturini and D. Generali, Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis, Lancet Oncol. 20(10) (2019) 1360–1369; https://doi.org/10.1016/S1470-2045(19)30420-6
- R. Addeo, P. Iodice, L. Maiorino, A. Febbraro, P. Incoronato, A. Pisano, M. Bianco, R. Mabilia, F. Riccardi and S. Del Prete, Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: exacampania group study, Breast J. 21(3) (2015) 326–328; https://doi.org/10.1111/tbj.12409
- C. McCowan, J. Shearer, P. T. Donnan, J. A. Dewar, M. Crilly, A. M. Thompson and T. P. Fahey, Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer, Br. J. Cancer 99(11) (2008) 1763–1768; https://doi.org/10.1038/sj.bjc.6604758
- C. Owusu, D. S. M. Buist, T. S. Field, T. L. Lash, S. S. Thwin, A. M. Geiger, V. P. Quinn, F. Frost, M. Prout, M. U. Yood, F. Wei and R. A. Silliman, Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer, J. Clin. Oncol. 26(4) (2008) 549–555; https://doi.org/10.1200/JCO.2006.10.1022
- R. L. Sedjo and S. Devine, Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer, Breast Cancer Res. Treat. 125(1) (2011) 191–200; https://doi.org/10.1007/s10549-010-0952-6
- R. Simon, J. Latreille, C. Matte, P. Desjardins and E. Bergeron, Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up, Can. J. Surg. 57(1) (2014) 26–32; https://doi.org/10.1503/cjs.006211
- V. Wong, R. de Boer, S. Baron-Hay, R. Blum, F. Boyle, S. Chua, K. Clarke, K. Cuff, M. Green, E. Lim, K. Mok, L. Nott, M. Nottage, A. Tafreshi, D. Tsoi, A. Uccellini, W. Hong, P. Gibbs and S.W. Lok, Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer, Clin. Breast Cancer 22(8) (2022) 792–800; https://doi.org/10.1016/j.clbc.2022.08.011
- M. Piezzo, P. Chiodini, M. Riemma, S. Cocco, R. Caputo, D. Cianniello, G. Di Gioia, V. Di Lauro, F. Di Rella, G. Fusco, G. Iodice, F. Nuzzo, C. Pacilio, M. Pensabene and M. De Laurentiis, Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis, Int. J. Mol. Sci. 21(17) (2020) Article ID 6400 (17 pages); https://doi.org/10.3390/ijms21176400
- C. Bandiera, I. Locatelli, P. Courlet, E. Cardoso, K. Zaman, A. Stravodimou, A. Dolcan, A. Sarivalasis, J. P. Zurcher, V. Aedo-Lopez, J. Dotta-Celio, S. Peters, M. Guidi, A. D. Wagner, C. Csajka and M. P. Schneider, Adherence to the CDK 4/6 inhibitor palbociclib and omission of dose management supported by pharmacometric modelling as part of the OpTAT study, Cancers (Basel) 15(1) (2023) Article ID 316 (19 pages); https://doi.org/10.3390/cancers15010316
- C. C. Conley, M. K. McIntyre, N. A. Pensak, F. Lynce, D. Graham, R. Ismail-Khan, K. Lopez, S. T. Vadaparampil and S. C. O’Neill, Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study, Breast Cancer Res. Treat. 192(2) (2022) 385–399; https://doi.org/10.1007/s10549-022-06518-2
- L. Turković, L. Bočkor, O. Ekpenyong, T. Silovski, M. Lovrić, S. Crnković, B. Nigović and M. Sertić, Development and validation of a novel LC-MS/MS method for the simultaneous determination of abemaciclib, palbociclib, ribociclib, anastrozole, letrozole, and fulvestrant in plasma samples: a pre-requisite for personalized breast cancer treatment, Pharmaceuticals 15(5) (2022) Article ID 614 (19 pages); https://doi.org/10.3390/ph15050614
- A. H. Y. Chan, R. Horne, M. Hankins and C. Chisari, The medication adherence report scale: a measurement tool for eliciting patients’ reports of nonadherence, Br. J. Clin. Pharmacol. 86(7) (2020) 1281–1288; https://doi.org/10.1111/bcp.14193
- R. Horne, K. Faasse, V. Cooper, M. A. Diefenbach, H. Leventhal, E. Leventhal and K. J. Petrie, The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability, Br. J. Health Psychol. 18(1) (2013) 18–30; https://doi.org/10.1111/j.2044-8287.2012.02071.x
- R. Horne, J. Weinman and M. Hankins, The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication, Psychol. Health 14(1) (1999) 1–24; https://doi.org/10.1080/08870449908407311
- R. Horne and J. Weinman, Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness, J. Psychosom. Res. 47(6) (1999) 555–567; https://doi.org/10.1016/S0022-3999(99)00057-4
- D. Wild, A. Grove, M. Martin, S. Eremenco, S. McElroy, A. Verjee-Lorenz and P. Erikson, Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation, Value Health 8(2) (2005) 94–104; https://doi.org/10.1111/j.1524-4733.2005.04054.x
- A. T. Beck, R. Steer, J. Brown, Manual for the Beck Depression Inventory-II; Psychological Corporation, San Antonio 1996.
- C. Louwrens Braal, E. M. Jongbloed, S. M. Wilting, R. H. J. Mathijssen, S. L. W. Koolen and A. Jager, Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences, Drugs 81(3) (2021) 317–331; https://doi.org/10.1007/s40265-020-01461-2
- K. Tamura, H. Mukai, Y. Naito, K. Yonemori, M. Kodaira, Y. Tanabe, N. Yamamoto, S. Osera, M. Sasaki, Y. Mori, S. Hashigaki, T. Nagasawa, Y. Umeyama and T. Yoshino, Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients, Cancer Sci. 107(6) (2016) 755–763; https://doi.org/10.1111/cas.12932
- T. S. Samant, S. Dhuria, Y. Lu, M. Laisney, S. Yang, A. Grandeury, M. Mueller-Zsigmondy, K. Umehara, F. Huth, M. Miller, C. Germa and M. Elmeliegy, Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations, Clin. Pharmacol. Ther. 104(2) (2018) 374–383; https://doi.org/10.1002/cpt.940
- A. Le Marouille, E. Petit, C. Kaderbhaï, I. Desmoulins, A. Hennequin, D. Mayeur, J. D. Fumet, S. Ladoire, Z. Tharin, S. Ayati, S. Ilie, B. Royer and A. Schmitt, Pharmacokinetic/pharmacodynamic model of neutropenia in real-life palbociclib-treated patients, Pharmaceutics 13(10) (2021) Article ID 1708 (14 pages); https://doi.org/10.3390/pharmaceutics13101708
- P. Courlet, E. Cardoso, C. Bandiera, A. Stravodimou, J. P. Zurcher, H. Chtioui, I. Locatelli, L. A. Decosterd, L. Darnaud, B. Blanchet, J. Alexandre, A. D. Wagner, K. Zaman, M. P. Schneider, M. Guidi and C. Csajka, Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer, Pharmaceutics 14(7) (2022) Article ID 1317 (17 pages); https://doi.org/10.3390/pharmaceutics14071317
- P. Kardas, P. Lewek and M. Matyjaszczyk, Determinants of patient adherence: a review of systematic reviews, Front. Pharmacol. 4 (2013) Article ID 91 (16 pages); https://doi.org/10.3389/fphar.2013.00091
- G. Kimmick, S. N. Edmond, H. B. Bosworth, J. Peppercorn, P. K. Marcom, K. Blackwell, F. J. Keefe and R. A. Shelby, Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy, Breast 24(5) (2015) 630–636; https://doi.org/10.1016/j.breast.2015.06.010
- H. Wouters, A. M. Stiggelbout, M. L. Bouvy, G. A. Maatman, E. C. G. Van Geffen, R. Vree, J. W. Nortier and L. Van Dijk, Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence, Clin. Breast Cancer 14(6) (2014) 460–467; https://doi.org/10.1016/j.clbc.2014.04.005
- C. Bolman, T. G. Arwert and T. Völlink, Adherence to prophylactic asthma medication: habit strength and cognitions, Heart Lung 40(1) (2011) 63–75; https://doi.org/10.1016/j.hrtlng.2010.02.003
- L. Alison Phillips, H. Leventhal and E. A. Leventhal, Assessing theoretical predictors of long-term medication adherence: patients’ treatment-related beliefs, experiential feedback and habit development, Psychol. Health 28(10) (2013) 1135–1151; https://doi.org/10.1080/08870446.2013.793798
- A. S. Gadkari and C. A. Mchorney, Unintentional non-adherence to chronic prescription medications: how unintentional is it really?, BMC Health Serv. Res. 12 (2012) Article ID 98 (12 pages); https://doi.org/10.1186/1472-6963-12-98
- M. Meegdes, S. M. E. Geurts, F. L. G. Erdkamp, M. W. Dercksen, B. E. P. J. Vriens, K. N. A. Aaldering, M. J. A. E. Pepels, L. M. H. van de Winkel, N. J. A. Teeuwen, M. de Boer and V. C. G. Tjan-Heijnen, The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: a study of the Dutch SONABRE Registry, Int. J. Cancer 150(1) (2022) 124–131; https://doi.org/10.1002/ijc.33785
- F. Després, A. Forget, F.-Z. Kettani and L. Blais, Impact of patient reimbursement timing and patient out-of-pocket expenses on medication adherence in patients covered by private drug insurance plans, J. Manag. Care Spec. Pharm. 22(5) (2016) 539–547; https://doi.org/10.18553/jmcp.2016.22.5.539
- S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth and R. J. Glynn, Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment, Circulation 115(16) (2007) 2128–2135; https://doi.org/10.1161/CIRCULATIONAHA.106.665992
- M. E. Patterson, S. J. Blalock, A. J. Smith and M. D. Murray, Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older, Clin. Ther. 33(5) (2011) 608–616; https://doi.org/10.1016/j.clinthera.2011.04.022
- S. Gupta, M. A. McColl, S. J. Guilcher and K. Smith, Cost-related nonadherence to prescription medications in Canada: a scoping review, Patient Prefer. Adherence 12 (2018) 1699–1715; https://doi.org/10.2147/PPA.S170417
- L. Husinka, P. H. Koerner, R. T. Miller and W. Trombatt, Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer, J. Drug Assess. 10(1) (2021) 27–34; https://doi.org/10.1080/21556660.2020.1857103
- A. Marra and G. Curigliano, Are all cyclin-dependent kinases 4/6 inhibitors created equal?, NPJ Breast Cancer 5 (2019) Article ID 27 (9 pages); https://doi.org/10.1038/s41523-019-0121-y
- J. L. Grenard, B. A. Munjas, J. L. Adams, M. Suttorp, M. Maglione, E. A. McGlynn and W. F. Gellad, Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis, J. Gen. Intern. Med. 26(10) (2011) 1175–1182; https://doi.org/10.1007/s11606-011-1704-y
- B. T. Mausbach, R. B. Schwab and S. A. Irwin, Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis, Breast Cancer Res. Treat. 152(2) (2015) 239–246; https://doi.org/10.1007/s10549-015-3471-7
- C. Burgess, V. Cornelius, S. Love, J. Graham, M. Richards and A. Ramirez, Depression and anxiety in women with early breast cancer: five year observational cohort study, Br. Med. J. 330(7493) (2005) 702–705; https://doi.org/10.1136/bmj.38343.670868.D3
- K. M. Christie, B. E. Meyerowitz and R. C. Maly, Depression and sexual adjustment following breast cancer in low-income Hispanic and non-Hispanic white women, Psychooncology 19(10) (2010) 1069–1077; https://doi.org/10.1002/pon.1661
- F. Trinca, P. Infante, R. Dinis, M. Inácio, E. Bravo, J. Caravana, T. Reis and S. Marques, Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies, Ecancermedicalscience 13 (2019) Article ID 937 (20 pages); https://doi.org/10.3332/ecancer.2019.937
- M. Thakur, R. Sharma, A. K. Mishra and K. R. Singh, Prevalence and psychobiological correlates of depression among breast cancer patients, Indian J. Surg. Oncol. 12(2) (2021) 251–257; https://doi.org/10.1007/s13193-021-01296-7
- C. Brito, C. Portela, M. Teixeira and L. De Vasconcellos, Adherence to hormone therapy among women with breast cancer, BMC Cancer 14 (2014) Article ID 397 (8 pages); https://doi.org/10.1186/1471-2407-14-397